Layoffs at Rapt Therapeutics after winding down mid-stage trials of lead drug
Rapt Therapeutics is slashing its headcount by 40% to extend its cash runway, just months after it ended Phase 2 studies of its lead immunology …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
